Download Files:
Bexotegrast
$150 – $4,600
Products Details
Product Description
– Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung[1][2].
Web ID
– HY-137561
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C27H36N6O3
References
– [1]Anindya Roy, et al. De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8. Nat Commun. 2023 Sep 13;14(1):5660.|[2]Martin L Decaris, et al. Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265.
CAS Number
– 2376257-44-0
Molecular Weight
– 492.61
Compound Purity
– 98.09
SMILES
– OC([C@H](CCN(CCOC)CCCCC(N1)=CC=C2C1=NCCC2)NC3=NC=NC4=C3C=CC=C4)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Integrin
Isoform
– αvβ1;αvβ6
Pathway
– Cytoskeleton
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
